In conclusion, we demonstrate that dasatinib strongly antagonizes BCR-ABL induced effects in vivo in a transgenic mouse model of chronic phase-CML, but had differential effects on hematopoiesis in wt mice. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.